Summary not available.
Axonics, a global medical technology company, will participate in two upcoming investor conferences. The first is the BofA Securities Healthcare Conference on May 9 at 2:20 p.m. ET, followed by the RBC Capital Markets Healthcare Conference on May 16 at 4:05 p.m. ET. Interested investors can access live webcasts and replays on the Axonics investor relations website.
Axonics focuses on developing products for bladder and bowel dysfunction and has been recognized for rapid growth, ranking No. 2 in the 2023 Financial Times and No. 4 in the 2022 Deloitte Technology Fast 500.
Axonics, Inc. (NASDAQ: AXNX), a medical technology company, has acquired a lead placement solution from Radian, LLC, enhancing its sacral neuromodulation (SNM) product line. The new technology promises to simplify the peripheral nerve evaluation (PNE) process, allowing for easier, faster, and more accurate lead placements without real-time imaging. This innovation is anticipated to reduce procedure times, bolster physician confidence, and increase adoption rates of SNM therapy. Axonics expects FDA clearance and commercialization by mid-2024. The acquisition is aligned with the company's goal of improving patient and physician experiences in treating bladder and bowel dysfunction.
Axonics, Inc. (NASDAQ: AXNX) will report its first quarter 2023 financial results after market close on May 1, 2023. A conference call is scheduled for 4:30 p.m. Eastern Time to discuss these results. Interested parties can register for the call via the provided link or join the webcast. Axonics specializes in innovative treatments for bladder and bowel dysfunction and has gained recognition, ranking No. 2 in the 2023 Financial Times fastest-growing companies in the Americas and No. 4 in the Deloitte Technology Fast 500 for 2022. The company offers clinically proven products, such as sacral neuromodulation systems and Bulkamid® for urinary incontinence, affecting millions of adults in the U.S. Furthermore, reimbursement for its services is well-established in the U.S. and most European territories.
Axonics, Inc. (NASDAQ: AXNX) has achieved a notable milestone by ranking No. 2 on the Financial Times list of the fastest growing companies in the Americas for 2023, following a No. 1 ranking in 2022. The company's revenue surged from $707,000 in 2018 to $180.3 million in 2021, reflecting a remarkable compound annual growth rate of 534% over this period. CEO Raymond W. Cohen highlighted this recognition as a testament to employee dedication and a commitment to innovation, aiming to raise awareness of bladder and bowel dysfunction treatments.
Axonics, Inc. (Nasdaq: AXNX) is a global medical technology company focused on bladder and bowel dysfunction solutions. The company will participate as a platinum sponsor at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2023 Winter Meeting in Nashville from March 7-11. Axonics will host a symposium on March 10 to discuss findings from the ARTSTRY registry study on sacral neuromodulation therapy. Additionally, three poster presentations will cover the effects of age on SNM effectiveness, improvements in sleep quality for nocturia patients, and the predictive programming algorithm's efficacy. Axonics aims to enhance life quality for those suffering from incontinence.
Axonics, Inc. (AXNX) announced record quarterly revenue of $86 million, marking a 62% increase year-over-year. For fiscal year 2022, revenue reached $274 million, up 52% compared to the previous year. The company reiterated its 2023 revenue guidance of $342 million, projecting 25% growth year-over-year. Notable performance included $70.3 million in sacral neuromodulation revenue. Adjusted EBITDA was $10 million for Q4 2022, a significant turnaround from a loss of $6.7 million the prior year. Cash reserves stand at $357 million. CEO Raymond W. Cohen highlighted strong product demand and innovation efforts in driving market expansion.
Axonics, Inc. (NASDAQ: AXNX), a medical technology firm focused on bladder and bowel dysfunction, is set to release its fourth quarter 2022 financial results on March 1. A conference call will be held at 4:30 p.m. Eastern Time for discussion. Axonics has gained recognition, ranking No. 1 in the Financial Times Fastest Growing Companies in the Americas and No. 4 in Deloitte's Technology Fast 500 in 2022. Their sacral neuromodulation systems and Bulkamid® treatment are clinically effective options for managing overactive bladder and fecal incontinence, with established reimbursement across the U.S. and many European nations.
Axonics, Inc. (NASDAQ: AXNX) has received FDA approval for its fourth-generation rechargeable sacral neuromodulation system, the Axonics R20™ neurostimulator. This device boasts a functional life of at least 20 years and requires recharging every 6 to 10 months, significantly enhancing patient convenience compared to the previous version, which needed monthly recharges. The R20 will launch commercially in the U.S. in March. Axonics emphasizes its commitment to improving patient outcomes in bladder and bowel dysfunction, reflecting strong market potential, particularly as awareness of sacral neuromodulation increases among the public.
Axonics anticipates fourth quarter 2022 net revenue of $85.6 to $86.0 million, marking a 61% year-over-year increase. For fiscal year 2022, total net revenue is projected at $273.6 million, reflecting a 52% rise. Furthermore, 2023 revenue guidance expects $342 million, a 25% growth year-over-year. The company attributes growth to increasing demand for its incontinence products, particularly the Axonics F15™ system and Bulkamid®, which treated over 50,000 women in 2022.